The life sciences sector’s reliance on artificial intelligence is deepening, and Colait is making a clear bet on experience over hype. The AI-powered platform, which helps pharmaceutical, biotechnology and medtech companies engage clinical experts and manage critical commercial workflows, has named Susan McNair as its new Senior Vice President.
McNair arrives with more than three decades of experience spanning the pharmaceutical, biotechnology and broader healthcare sectors. Her background includes deep expertise in medical communications, key opinion leader (KOL) engagement, physician relationships and strategic life sciences programs. She has held leadership roles at major healthcare organizations, including Cardinal Health, as well as healthcare communications and consulting firms such as AXON Communications, part of Avenir Global.
Throughout her career, McNair has worked directly with pharmaceutical and biotechnology companies, supporting strategic physician engagement initiatives, advisory boards, clinical investigator programs and communications. She also brings hands-on experience with technology platforms designed for thought leader identification, management and engagement. This combination of industry knowledge and tech fluency is expected to bolster Colait as it accelerates its global expansion and refines its AI-powered platform.
Also worth a look: cplace AI Builder challenges enterprises to govern apps built in hours, not months and Vadzo Imaging validates 20MP camera for remote sites where bandwidth is scarce.
“Susan brings exactly the kind of deep industry experience and understanding that is central to what we are building at Colait,” said Colette Balaam, CEO of Colait. “She has spent decades working alongside pharmaceutical companies, physicians and leading clinical experts, and understands the importance of meaningful, trusted relationships in healthcare. Her experience across medical communications, KOL engagement and technology makes her a tremendous addition to our team as we advance our global ambitions.”
“I am excited to join Colait at such an important stage in its evolution,” said McNair. “The opportunity to bring together decades of experience in physician engagement and life sciences with the possibilities of AI is incredibly compelling. Colait is addressing important challenges facing the industry, and I look forward to helping advance the company’s work with pharmaceutical, biotechnology and healthcare organizations around the world.”
McNair’s appointment further strengthens Colait’s leadership and industry expertise as the company expands its global reach and develops AI-powered capabilities for pharmaceutical, biotechnology and medtech organizations.
About Colait
Colait is transforming how the global life sciences industry accesses expertise, generates clinical intelligence and executes critical workflows. Combining a global network of clinicians with AI-powered technology, Colait enables pharmaceutical, biotechnology and medtech organizations to harness expert perspectives, generate actionable insights and deploy intelligent agents across commercial, medical affairs, market access and other critical business functions.
For more information, visit www.colait.com.
Colette Balaam
Colait
Visit us on social media:
Other
Why it matters: As AI reshapes how drug companies identify and engage with key opinion leaders, hiring leaders who understand both the science and the relationship dynamics becomes critical. McNair’s appointment signals that Colait is betting on deep domain expertise—not just technology—to win trust in a heavily regulated industry where credibility is everything.
